Lanadelumab

DRUG13 trials

Conditions

AngioedemaCOVID-19COVID-19 PneumoniaHealthy VolunteersHereditary AngioedemaHereditary Angioedema (HAE)Hereditary Autoinflammatory DiseaseLung Injury

Phase 1

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

CompletedNCT03401671

ShireHealthy Volunteers

Start: 2018-01-15End: 2018-05-30Updated: 2021-06-03

Lanadelumab for Treatment of COVID-19 Disease

CompletedNCT04422509

Radboud University Medical CenterCOVID-19

Start: 2020-10-30End: 2021-04-30Updated: 2021-07-13

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

WithdrawnNCT04460105

ShireCOVID-19 Pneumonia

Start: 2020-10-31End: 2021-01-27Updated: 2020-10-12

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

CompletedNCT04503603

TakedaHealthy Volunteers

Start: 2020-08-10End: 2020-12-23Updated: 2022-03-07

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Active, not recruitingNCT04848272

St Vincent's Institute of Medical ResearchLung Injury

Start: 2021-08-09End: 2024-12-31Target: 48Updated: 2024-04-17

Phase 2

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Active, not recruitingNCT04278885

Charite University, Berlin, GermanyHereditary Autoinflammatory Disease

Start: 2020-10-05End: 2024-12-31Updated: 2024-01-08

Phase 3

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

CompletedNCT04070326

ShireHereditary Angioedema

Start: 2019-08-19End: 2021-10-30Updated: 2022-05-26

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

CompletedNCT04180163

ShireHereditary Angioedema (HAE)

Start: 2019-12-12End: 2021-08-26Updated: 2022-09-30

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

CompletedNCT04206605

TakedaAngioedema

Start: 2020-05-04End: 2022-10-20Updated: 2023-12-27

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

CompletedNCT04444895

ShireAngioedema

Start: 2021-02-05End: 2023-05-05Updated: 2024-06-17

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

CompletedNCT04590586

AmgenCOVID-19

Start: 2020-11-24End: 2021-08-03Updated: 2022-06-29

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

CompletedNCT05460325

TakedaHereditary Angioedema (HAE)

Start: 2022-06-22End: 2023-11-28Updated: 2024-12-13

Unknown Phase

A Survey of Lanadelumab in Participants With Hereditary Angioedema

CompletedNCT05397431

TakedaHereditary Angioedema (HAE)

Start: 2022-05-30End: 2026-01-31Updated: 2026-02-04

Frontiers in Immunology2025-05-211 citations

Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.

2025-01-21

Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study.

2023-09-1816 citations

Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label study

The Journal of Dermatology2023-08-146 citations

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

Allergy Asthma and Clinical Immunology2022-09-243 citations